drugset / Trial / NCT06042010

Oral Zinc Supplement as Adjunctive Therapy for Erosive Oral Lichen Planus

NCT06042010

Completed 22 enrolled Hams Hamed Abdelrahman
RandomizedParallel-groupOpen-labelTreatment

Summary

Lichen Planus (LP) is a chronic mucocutaneous inflammatory disease and considered as T-cell mediated autoimmune disorder. Zinc is a potent antioxidant micronutrient that contributes to the proper functioning of the antioxidant defense system. In addition, this mineral protects cells against inflammation by oxidative stress, because it acts in the stabilization of cell membrane. It also maintains macrophage and neutrophil functions, natural killer cell activity, and complement activity. Matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases and have the main function of proteolytic degradation of connective tissue matrix proteins. Zinc prevents (MMP-1) activation and inhibition of the T-cell accumulation in (OLP) through inhibiting of (MMP-9). Aim of the study: To evaluate and compare the efficacy of adding oral zinc supplementation 50 mg to 0.1%Triamcinolone orabase (TA)versus 0.1%Triamcinolone orabase alone on the healing of erosive OLP.

Timeline

Start
2023-01-05
Primary completion
2023-02-14
Completion
2023-02-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Triamcinolone Acetonide Other / unclassified 0.1 % Oral
Subject Zinc Sulfate Unknown 50 mg Oral

Indications